OPTIONS
Country Situation Analysis Interim Findings: Kenya

FSG in partnership with LVCT Health
OPTIONS Introduction

One of five cooperative agreements awarded by USAID with PEPFAR funding through Round Three of the Annual Program Statement (APS) for Microbicide Research, Development, and Introduction.

The OPTIONS Consortium objective is to provide targeted support to help expedite and sustain access to new ARV-based HIV prevention products in countries and among populations where most needed.

OPTIONS Consortium Members
## OPTIONS Consortium Aims

OPTIONS can provide targeted support across its four project aims:

<table>
<thead>
<tr>
<th>AIM 1</th>
<th>AIM 2</th>
<th>AIM 3</th>
<th>AIM 4</th>
</tr>
</thead>
<tbody>
<tr>
<td>Develop evidence-based <em>business cases and a coordinated investment strategy</em> for ARV-based prevention product introduction to ensure timely global, national and private sector action on priority areas</td>
<td>Support <em>country level</em> regulatory approval, policy development, program planning, marketing and implementation strategies for ARV-based prevention product introduction</td>
<td>Facilitate and conduct <em>implementation science</em> (IS) to advance the introduction of and access to microbicides and ARV-based prevention technologies</td>
<td>Provide <em>technical assistance and support for health systems strengthening (HSS)</em> with rapid use of data to identify and address implementation bottlenecks throughout the value chain</td>
</tr>
</tbody>
</table>
OPTIONS How We Work

• OPTIONS is **not a service delivery** project; we apply **systems thinking to support and accelerate** product introduction

• Our support is flexible and is designed to be **responsive to national country priorities and plans** and will be **guided by national leadership** through NASCOP

• We have a **strong local partner**, LVCT Health, with significant experience working on HIV prevention in the Kenya context

• In addition to LVCT, our consortium is able to bring **multi-disciplinary expertise** to the effort to introduce female-controlled HIV prevention products in Kenya

• We are taking significant steps to ensure we do not replicate existing or ongoing work – our mission is to **fill gaps and help answer key questions** as outlined by the national government, the USAID country mission, and other key local stakeholders
About the Situation Analysis

- This document includes **interim findings** from the OPTIONS situation analysis for Kenya, completed by FSG with significant input and consultation from LVCT Health.

- The situation analysis aims to take a **comprehensive and robust approach** to assessing the “state of the field” for PrEP in Kenya, including opportunities and resources as well as gaps and expected challenges.

- The situation analysis serves **multiple purposes**: it provides a basis for country consultations and stakeholder engagement, it serves as a tool to clarify the roles, activities and investments needed for the successful roll-out of PrEP, and it will inform the development of the OPTIONS investment cases for PrEP.

- This document reflects findings from secondary **research** and in-country consultations with key stakeholders.

- This is designed as a **“living document,”** to serve as a repository for information regarding the situation of PrEP in Kenya to be updated on an ongoing basis as additional information becomes available and progress is made towards the roll-out of PrEP.

- If you have any **updates, additional information, or follow-up questions** regarding this situation analysis, please email Neeraja Bhavaraju at Neeraja.Bhavaraju@fsg.org.
Executive Summary

• Kenya has made strides toward creating positive initial conditions for the roll-out of PrEP:
  – PrEP is included in Kenya’s most recent national plans for combating HIV/AIDS including the Kenya AIDS Strategic Framework (KASF) and the Prevention Revolution Roadmap
  – The Pharmacy and Poisons Board has registered Truvada (oral PrEP) for HIV prevention
  – Government entities such as NASCOP are taking a proactive role in generating local-level buy-in for PrEP, engaging diverse sectors in PrEP planning, and cooperating with key stakeholders in the development of policies and practices for PrEP
  – Potential target populations have been initially defined: female sex workers (FSW), men having sex with men (MSM), sero-discordant couples, adolescent girls and young women (AGYW), among others

• Currently, there is no official implementation strategy for PrEP. Kenya, through NASCOP and CDC leadership, is in the process of translating high-level WHO policy into treatment and implementation guidelines, which are expected to be completed by June 2016 and involve multi-sector participation

• The current state of the PrEP discussion revolves around implementation considerations:
  – Defining priority target populations for PrEP
  – Finding key delivery channels for reaching target populations with PrEP (e.g., comprehensive care centers and other ART sites, DREAMS districts, sexual and reproductive health (SHR) sites)
  – Understanding target population user preferences and PrEP access needs, and deploying a successful national communications campaign for PrEP
  – Determining the cost and impact of adding PrEP to prevention strategies for target populations
  – Assessing capacity-building needs for the integration of PrEP into health services and other channels

• The most significant current concerns about PrEP include:
  – How to address stigma through policies, communications, and scale-up procedures
  – Obtaining donor commitment to sustainably fund scale-up of PrEP
HIV in Kenya

Context
- Kenya has the world’s **fourth largest HIV burden**, with an estimated **1.63 million** people living with HIV (prevalence of 6%)³
- **100,000 new infections** occur annually, with **21% of adult infections occurring among young women** ages 15-24²
- Highly **geographically concentrated HIV burden**, thus Government and PEPFAR’s response to HIV is focused at the county level

Trends
**HIV incidence has steadily been decreasing at a low rate**

**HIV incidence over time**³ (in millions)

- Male
- Female
- Total

Demographics
Kenya’s HIV incidence is driven by a **broad set of populations**, including significant contributions from sero-discordant couples and adolescent girls and young women (AGYW):

**New adult HIV infections, 2013²**

- 21% of new adult HIV infections occur among young women aged 15-24 every year
- 2.5% Health Facility Related
- 3.8% Injecting Drug Use (IDU)
- 15.2% MSM and Prison
- 44.1% Heterosexual sex within union
- 20.3% Casual heterosexual sex
- 14.1% Sex workers and Clients

Geography
**Highly concentrated epidemic- 65% of new infections occurring in 9 out of the 47 counties²:**

HIV Prevention & Treatment in Kenya

Context

• Through a heightened level of investment and a focus on combination prevention, the government has made significant progress in reducing the number of new infections: 44% decrease among infants; 7% among adults between 2008 and 2013¹

• Given the smaller reduction in adult infections, Kenya’s most current strategy has shifted towards focusing on priority geographies with high-incidence, and integrating those who are disproportionately affected by the epidemic: girls, women and key populations such as FSW, MSM, people who inject drugs (PWID), and people in prison²

Current Efforts

• High HIV/AIDS treatment coverage² in ~2000 ART sites:
  - Mother to child (78%)
  - Men (80%)
  - Women (77%)
  - Infants/children (42%)

• High reach of HIV testing and counselling for high-risk populations, with lower rates for general public² through ~5000 testing sites:
  - FSW (68%)
  - MSM (74%)
  - PWID (60%)
  - Women- general (47.3%)
  - Men- general (35.8%)

• Varying percent of key populations not receiving targeted interventions³:
  - FSW (30%)
  - MSM (45%)
  - PWID (76%)

Remaining Challenges

• Despite growing investment, Kenya is struggling with financial sustainability for HIV treatment and prevention, and has begun to develop additional domestic funding sources

• The current health service system faces challenges in planning, coordination, and inadequate infrastructure investment, leading to capacity constraints in HIV-AIDS clinics such as a shortages of staffing, insufficient space/facility infrastructure, and shortages in testing kits

• PLHIV continue to face high levels of stigma throughout the country

• Current messaging and distribution channels are insufficient for reaching key populations; the GoK will need to continue to adjust current strategies in order to serve at-risk populations, and invest in youth-friendly services/facilities

• Risk perception is low among certain target populations, which makes prevention uptake a constant challenge

Key Considerations for PrEP

Why PrEP is under consideration in Kenya

- **Achieving national targets:** Kenya has committed to addressing the HIV/AIDS epidemic by setting a high goal for prevention: a **75% reduction in new infections by 2020.**\(^1\) However, the rate of reduction for adult HIV transmission is slow, **seeing only a 7% decrease from 2007-2013.**\(^1\) At this rate, **Kenya will not meet its goals.** The number of new infections will not decrease unless Kenya targets at-risk populations who are most severely affected: **FSW, MSM, sero-discordant couples, PWID, AGYW, people in prison, and other marginalized populations.**\(^2\) PrEP could provide an effective method for these populations who do not use other prevention options.

- **Combination prevention:** Impact models suggest that **PrEP use by key populations** in combination with the currently available set of interventions (behaviour change, early ART, male circumcision) would **avert the highest number of infections.**\(^2\)

- **Equity and human rights:** Kenya’s national plan states that “the success of the HIV response is dependent on protecting and **promoting the rights** of those who are socially excluded, marginalised and vulnerable.”\(^1\) Several of the high-risk populations for whom PrEP is most appropriate are also most discriminated against by Kenyan society. Currently, demonstration projects have shown promising results for the demand for PrEP among these populations, **particularly among MSM and FSW.**\(^3\)

- **PrEP offers a gender-sensitive option for prevention:** Women continue to be **disproportionately affected by HIV/AIDS,** in particular AGYW ages 15-24. If implemented effectively, PrEP could give women the choice to protect themselves against infection, regardless of their partner’s preference for sexual activity.

Context and questions around PrEP

- Kenya’s national plans (KASF, Revolution Roadmap) include provision of PrEP to key populations severely affected by HIV

- The Pharmacy and Poisons Board approved PrEP in December 2015, and national treatment and implementation guidelines **expected** in June 2016

- Although national plans and policies include provisions for PrEP, questions remain on concrete plans to deliver PrEP to target populations, plans to encourage and support uptake, and funding for PrEP

- Remaining questions about the most effective delivery channels for distribution of PrEP, as well as the health care system capacity to reach key populations and provide additional PrEP-related services

- Funding for PrEP is still unclear, yet donors such as Gates and PEPFAR have shown initial commitments to fund PrEP introduction in Kenya

- Planning for PrEP will likely be initially focused on high-priority, high-burden geographic regions within Kenya

What’s Needed to Introduce PrEP

OPTIONS aims to take a robust and comprehensive approach to analyzing the situation around PrEP. The goal of this exercise is to identify key bottlenecks and opportunities to introduce and scale PrEP effectively in each OPTIONS country. This information will eventually feed into the investment cases and will be used to inform and capture country progress.

To identify what’s needed for PrEP introduction, we have organized the rest of the situation analysis along the PrEP value chain, introduced below.

Value Chain for PrEP

- **PLANNING AND BUDGETING**: Plan developed to implement WHO PrEP guidelines for targeted populations
- **SUPPLY CHAIN MANAGEMENT**: PrEP produced, purchased, and distributed in sufficient quantity to meet projected demand
- **PREP DELIVERY PLATFORMS**: PrEP services delivered by appropriate channels with access to target populations
- **INDIVIDUAL UPTAKE**: Target populations seek and are able to access PrEP and begin use
- **EFFECTIVE USE & MONITORING**: Target population adheres to PrEP at recommended frequency and for ideal time period
Value Chain Analyses

The following slides hold three analyses along the value chain:

- **Resources** that exist in-country to support and accelerate PrEP introduction
- **Gaps** in resources that could act as barriers to effective PrEP introduction
- **Key considerations** to inform comprehensive in-country planning for PrEP introduction

A list of **specific factors** that need to be in-place to effectively introduce PrEP for each component of the value chain along with progress to-date for each factor

Details on current situation, **key actors**, responsibilities, **timelines** and progress towards each activity are included in the appendix

- **Remaining questions to inform in-country discussions** and planning
- **Remaining questions to inform ongoing modelling, research and analysis** efforts
- **Opportunities for other partners** to support acceleration of PrEP introduction
Resources and Gaps for PrEP in Kenya

**Expected Strengths**

- National plans call for using **PrEP within current combination prevention** for FSW, MSM and serodiscordant couples in high-burden counties
- Truvada is now registered for prevention
- PrEP national guidelines expected in June 2016
- **Procurement processes** have effectively supplied ARVs without shortages through a strong e-system
- Current distribution channels for HIV testing and counselling are **widespread and diverse**
- Health system has **high reach** of some at-risk groups such as FSW and MSM
- **High reach and usage of HIV testing/counselling services for at-risk populations**
- Demonstration projects will provide insight on user needs and preferences for PrEP
- National HIV M&E plan to measure progress is in place. NASCOP and partners plan to develop a national **PrEP M&E plan**
- Demo projects are generating insights on **effective use concerns**

**Emerging Key Considerations**

- Implications of PrEP for **AGYW** remain uncertain; demonstration projects will provide additional data and insights
- Sources of **financing** for PrEP are uncertain
- **PrEP could use existing supply chain systems** for ARVs, but new delivery channels would require additional planning
- **County coordination and targeting** will require consideration
- Health system will need **additional capacity** (e.g., staff, equipment) to deliver PrEP
- **Channels for PrEP** will need to be identified for target populations including AGYW
- **Stigma is a major concern** for uptake in AGYW and sero-discordant couples
- **Awareness / demand** for PrEP is unknown; will require investment in demand generation
- Need **communications campaign** for PrEP
- **Ongoing testing for PrEP users** may put additional strain on health system capacity
- Strategies are needed to encourage **effective use** for each target population
# Towards Introduction of PrEP in Kenya

## PLANNING & BUDGETING

- **Impact, cost and cost-effectiveness analyses** for PrEP as part of comprehensive HIV prevention portfolio
- **Identification and quantification of target populations** for PrEP
- **Inclusion of PrEP and female-controlled methods** in current or upcoming national HIV prevention plans
- **Timeline and plan** for PrEP introduction and scale-up
- **A budget** for PrEP roll-out to target populations
- **Sufficient funding** to achieve targets

## SUPPLY CHAIN MANAGEMENT

- **Regulatory approval** of form(s) of oral PrEP by authorities
- **Effective demand and supply forecasting** mechanisms for PrEP
- **Manufacturer identification and contract** negotiation to purchase PrEP
- **Product and packaging design** to meet target population needs and preferences
- **Development of distribution plan** for PrEP to reach target populations
- **Effective distribution mechanisms** to avoid PrEP stock-outs in priority facilities

## PREP DELIVERY PLATFORMS

- **Issue of standard clinical guidelines** for prescription and use of PrEP
- **Sufficient infrastructure and human resources** to conduct initial HIV tests and prescribe PrEP in priority channels
- **Plan to engage health care workers** on PrEP and delivery to target populations (including mitigating stigma)
- **Tools to help potential clients and HCW understand who should use PrEP** have been created
- **Sufficient resources** to roll-out plans for healthcare worker engagement

## INDIVIDUAL UPTAKE

- **Clear and informative communications** on PrEP for general public audiences
- **Development of demand generation strategies** targeted to unique needs of different populations
- **Linkages** between HTC, PrEP prescription, and PrEP access to enable PrEP uptake
- **Information for clients** on how to effectively use PrEP for all target populations

## EFFECTIVE USE & MONITORING

- **Established plans to support effective use and regular HIV, creatinine testing** that reflect the unique needs of target populations
- **Capacity** to provide ongoing HIV and creatinine level testing for PrEP users accessible to target populations
- **Monitoring system** to support data collection for ongoing learning (e.g., rate of patients returning for 2nd visit, non-HIV STI rates)

## COLOR KEY

- **Green**: Significant progress and/or momentum
- **Orange**: Early progress
- **Gray**: Initial conversations ongoing
Key Questions for PrEP in Kenya

- **What is the incremental cost and impact** of adding PrEP to combination prevention for target populations in target geographies?
- **To what extent are target populations willing and able to pay** for PrEP?
- **How will the introduction of PrEP be financed?**

- **Who will manufacture PrEP?** How will it be priced / packaged? What alternatives could be used?
- **How will PrEP procurement and distribution** be managed between the national and county levels, particularly for potential channels that are not delivering ARVs?

- **What are the most effective channels** to reach target populations with PrEP (e.g., health facilities, community channels)?
- **How will health care workers, including community health workers, be engaged and supported to deliver PrEP?**

- **What is the current demand generation strategy** for PrEP?
- **How will stigma be addressed** both to ensure target populations can effectively access PrEP and to ensure that use by some (e.g., FSW) does not stigmatize PrEP for others (e.g., AGYW)?

- **What will be considered “effective use”** for each population and how will it be encouraged?
- **To what extent will ongoing testing needs for PrEP users further strain health systems capacity?**
- **How will ongoing monitoring be managed?**

**PLANNING AND BUDGETING**

**SUPPLY CHAIN MANAGEMENT**

**PREP DELIVERY PLATFORMS**

**INDIVIDUAL UPTAKE**

**EFFECTIVE USE & MONITORING**
Key Stakeholders for PrEP

**PLANNING & BUDGETING**

- **Kenya Ministry of Health**: creates national plans/priorities, and oversees the following HIV-specific divisions
- **NACC**: implements strategic plans, coordinates stakeholders, leverages resources, and provides care for PLHIV
- **NASCOP**: oversees policy and guidelines, coordinates technical HIV programming, manages supply chains and capacity-building, performs M&E
- **National technical working groups**: provide leadership and strategic guidance for implementation

- **CDC**: involved in guideline creation

**SUPPLY CHAIN MANAGEMENT**

- **Pharmacy and Poisons Board**: approves all new medications
- **Gilead**: registered Truvada for prevention in Kenya
- **Kenya Medical Supplies Authority**: central procurement agency

**PREP DELIVERY PLATFORMS**

**INDIVIDUAL UPTAKE**

- **Professional regulators**: (Medical Pract. & Dentists Board, Nursing Council) - gives licensure to health providers, and monitors ethical practice of health workers

- **CDC**: supplies laboratory capacity support

**EFFECTIVE USE & MONITORING**

- **National HIV Reference Laboratory**: improves country’s HIV lab capacity

**Countylevel governments**: make decisions regarding planning, funding, procurement/distribution, and health facility capacity-building for PrEP

- **Health care facilities**: (community-based clinics, SWOP clinics, comprehensive care clinics, mobile clinics, HTC sites) - provide ARVS and other HIV/AIDS-related services

- **Community based organizations**: (non-profit, faith-based, advocacy groups) - trusted organizations that can reach target populations with PrEP and generate demand

**Specific organizations will be determined upon national level implementation plans**

**Donors**

- **Current donors**: (PEPFAR, Gates Foundation, and Nike Foundation as part of DREAMS) CHAI, Global Fund, UNAIDS and WHO

- **Other potential donors**: (HNWIs, local philanthropic organizations, UKAID, UNITAID)
County-level HIV structures in Kenya

County governments are responsible for developing HIV prevention budgets and implementation plans at the local level, and therefore will be critical partners in any efforts to introduce PrEP in Kenya.

**County-level governance structures for HIV**

**National Government** coordinates functions of ministries and government departments to reinforce NACC’s role; coordinates allocation of funding to districts

**County Government (Governor)** implements national policy and ensures resource allocation for HIV programs

**County Executive Committee** oversees effective delivery of the HIV response at the county level

**County HIV Committee** ensures effective delivery of the HIV response at the county level

**County HIV Coordination Unit (NACC)** coordinates implementation of the KASF

**County Health Management Team** responsible for ensuring integration of HIV services at the county level

**NACC Secretariat** facilitates delivery of KASF, including accountability of sectors and partners involved and sustainable financing

**County HIV Inter-agency Coordinating Committee** comprised of stakeholder Working Groups representing the various constituencies e.g., CSO, FBOs, Youth, PWID, PLHIV coordinates and oversees implementation of global fund projects

**County KASF Monitoring Committee** county monitoring of KASF activities across five Strategic Direction areas of Prevention, Treatment, Human Rights, Systems Strengthening and Research

**Sub-County/Constituency HIV Committees** members of the County HIV Committee, responsible for the effective delivery of the HIV response at the sub-county level

APPENDIX

A. Value Chain Detail
B. Timeline for PrEP
C. References
Appendix A: Value Chain Detail

Towards Introduction of PrEP in Kenya

The following slides provide additional detail on each section of the PrEP value chain in Kenya.
Planning

### Readiness for PrEP Introduction

<table>
<thead>
<tr>
<th>Readiness Factor</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact, cost and cost-effectiveness analyses for PrEP as part of comprehensive HIV prevention portfolio</td>
<td>• Modelling studies underway to refine impact and cost-effectiveness estimates (Health Policy Project, Avenir) • Costing studies underway (CHAI/LVCT Health); expected Q4 2016</td>
</tr>
<tr>
<td>Identification and quantification of target populations for PrEP</td>
<td>• Target populations in Revolution Roadmap include FSW, MSM, PWID, sero-discordant couples, varied by county • Plans for AGYW remain uncertain</td>
</tr>
<tr>
<td>Inclusion of PrEP and female-controlled methods in current or upcoming national HIV prevention plans</td>
<td>• PrEP is mentioned in the KASF and included in Revolution Roadmap as part of recommended prevention interventions</td>
</tr>
<tr>
<td>Timeline and plan for PrEP introduction and scale-up</td>
<td>• Early considerations articulated • NASCOP has asked LVCT Health to support development of an implementation plan</td>
</tr>
<tr>
<td>A budget for PrEP roll-out to target populations</td>
<td>• Early budget considerations and thinking happening as part of broader PrEP planning</td>
</tr>
<tr>
<td>Sufficient funding to achieve targets</td>
<td>• DREAMS has resources dedicated to PrEP for AGYW • Gates Foundation has expressed interest in PrEP scale-up.</td>
</tr>
</tbody>
</table>

#### Key Stakeholders
- **MoH** - creates national plans/priorities, and oversees the following HIV-specific divisions:
- **NACC** - helps implement strategic plans, coordinates stakeholders, and provides care for PLHIV
- **NASCOP** - has oversight on policy and guidelines, coordinates technical HIV programming, manages capacity-building, and performs M&E
- **National technical working groups** - run by NASCOP and NACC, provide leadership and strategic guidance for implementation

#### Key Strengths and Opportunities
- **Target populations** and **target geographies** for PrEP are defined
- Government is leading efforts to **further disaggregate data to segment youth population**, including AGYW
- **Prevention Revolution Roadmap** makes the case for geographic targeting and combination prevention including PrEP for target populations
- **NASCOP** is engaging key stakeholders such as county-level governments, civil society and advocacy groups
- **Cost models** exist and are being refined for delivering and scaling PrEP to FSW and MSM

#### Key Emerging Considerations
- **More prep-specific information is needed for target populations:** preferences, needs for access and support, effective use (some will be available through demo project and Population Council research)
- Translating a national strategy into **county-level action** will require significant guidance and incentives (financial and technical support, leadership of other counties)
- **National funding is insufficient** for providing and sustaining PrEP; Kenya will need donors to scale-up PrEP

### Readiness Factor

<table>
<thead>
<tr>
<th>Readiness Factor</th>
<th>Progress</th>
</tr>
</thead>
<tbody>
<tr>
<td>Impact, cost and cost-effectiveness analyses for PrEP as part of comprehensive HIV prevention portfolio</td>
<td>• Modelling studies underway to refine impact and cost-effectiveness estimates (Health Policy Project, Avenir) • Costing studies underway (CHAI/LVCT Health); expected Q4 2016</td>
</tr>
<tr>
<td>Identification and quantification of target populations for PrEP</td>
<td>• Target populations in Revolution Roadmap include FSW, MSM, PWID, sero-discordant couples, varied by county • Plans for AGYW remain uncertain</td>
</tr>
<tr>
<td>Inclusion of PrEP and female-controlled methods in current or upcoming national HIV prevention plans</td>
<td>• PrEP is mentioned in the KASF and included in Revolution Roadmap as part of recommended prevention interventions</td>
</tr>
<tr>
<td>Timeline and plan for PrEP introduction and scale-up</td>
<td>• Early considerations articulated • NASCOP has asked LVCT Health to support development of an implementation plan</td>
</tr>
<tr>
<td>A budget for PrEP roll-out to target populations</td>
<td>• Early budget considerations and thinking happening as part of broader PrEP planning</td>
</tr>
<tr>
<td>Sufficient funding to achieve targets</td>
<td>• DREAMS has resources dedicated to PrEP for AGYW • Gates Foundation has expressed interest in PrEP scale-up.</td>
</tr>
</tbody>
</table>

#### Key Stakeholders
- **MoH** - creates national plans/priorities, and oversees the following HIV-specific divisions:
- **NACC** - helps implement strategic plans, coordinates stakeholders, and provides care for PLHIV
- **NASCOP** - has oversight on policy and guidelines, coordinates technical HIV programming, manages capacity-building, and performs M&E
- **National technical working groups** - run by NASCOP and NACC, provide leadership and strategic guidance for implementation

#### Key Strengths and Opportunities
- **Target populations** and **target geographies** for PrEP are defined
- Government is leading efforts to **further disaggregate data to segment youth population**, including AGYW
- **Prevention Revolution Roadmap** makes the case for geographic targeting and combination prevention including PrEP for target populations
- **NASCOP** is engaging key stakeholders such as county-level governments, civil society and advocacy groups
- **Cost models** exist and are being refined for delivering and scaling PrEP to FSW and MSM

#### Key Emerging Considerations
- **More prep-specific information is needed for target populations:** preferences, needs for access and support, effective use (some will be available through demo project and Population Council research)
- Translating a national strategy into **county-level action** will require significant guidance and incentives (financial and technical support, leadership of other counties)
- **National funding is insufficient** for providing and sustaining PrEP; Kenya will need donors to scale-up PrEP
## Potential Target Populations for PrEP

<table>
<thead>
<tr>
<th>Target Population</th>
<th>Key Indicators</th>
<th>Prioritization</th>
<th>Questions</th>
</tr>
</thead>
<tbody>
<tr>
<td>Adolescent girls and young women (AGYW)</td>
<td>~4.1M total AGYW (ages 15-24) in Kenya, based on 2009 Census¹</td>
<td>National plans define AGYW as a priority population for prevention; sometimes mentioned as targets for PrEP</td>
<td>What messages will be appropriate for encouraging use of PrEP without stigma?</td>
</tr>
<tr>
<td></td>
<td>21% of new adult infections per year are among AGYW³</td>
<td>Demonstration projects: Confidence Project, MP3-Youth, POWER, IPCC</td>
<td>Which channels will be effective for PrEP delivery?</td>
</tr>
<tr>
<td></td>
<td>4.5% prevalence; by age 24 the rate for AGYW is almost 4 times higher than for young boys²</td>
<td>Included in national plans as priority population for prevention; mentioned as targets for PrEP</td>
<td>What additional community support mechanisms need to be in place for PrEP’s effective use?</td>
</tr>
<tr>
<td></td>
<td>~90% of young women test for HIV at least once by the time they are age 24²</td>
<td>Demonstration projects: Fem-PrEP, Partners PrEP Ole</td>
<td>How much demand will there be for PrEP, especially relative to other prevention options in the pipeline?</td>
</tr>
<tr>
<td>Sero-discordant couples</td>
<td>~260,000 couples³ or 5-6%⁴ of couples are HIV sero-discordant</td>
<td>National plans define as priority population for prevention; mentioned as targets for PrEP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>44.1% of new adult infections from sero-discordant couples³</td>
<td>Demonstration project: IPCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Unknown level of access to testing and targeted HIV/AIDS intervention services</td>
<td>Existing study on cost of PrEP scale-up for FSW</td>
<td></td>
</tr>
<tr>
<td></td>
<td>Low awareness of partner status (48% for women; 61% for men)⁵</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Female Sex Workers (FSW)</td>
<td>Unknown number, but estimated at ~1000,000⁴*</td>
<td>National plans define FSW as a priority population for prevention; mentioned as targets for PrEP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>29.3% HIV prevalence ⁴</td>
<td>Demonstration project: IPCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>14.1% of new adult infections per year are among sex workers and their clients³</td>
<td>Existing study on cost of PrEP scale-up for FSW</td>
<td></td>
</tr>
<tr>
<td></td>
<td>68% tested for HIV in the past year and know their status⁶</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>70% receive targeted intervention services³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>People Who Inject Drugs (PWID)</td>
<td>Unknown number of total PWID*</td>
<td>National plans define PWID as a priority population for prevention</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.3% prevalence³</td>
<td>MSM mentioned as targets for PrEP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>3.8% of new adult infections per year³</td>
<td>Demonstration project: IPCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>60% tested for HIV in past year and know their status⁶</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>24% receive targeted intervention services³</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Men who have sex with men (MSM)</td>
<td>Unknown number of total MSM*</td>
<td>National plans define MSM as a priority population for prevention</td>
<td></td>
</tr>
<tr>
<td></td>
<td>18.2% prevalence³</td>
<td>MSM mentioned as targets for PrEP</td>
<td></td>
</tr>
<tr>
<td></td>
<td>15.2% of new adult infections per year from MSM and prison³</td>
<td>Demonstration project: IPCC</td>
<td></td>
</tr>
<tr>
<td></td>
<td>74% tested for HIV in the past year and know their status⁶</td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>55% receive targeted intervention services³</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Sources:**
2. Kenya Fast Track Plan to end HIV/AIDS in Adolescents and Young People, Ministry of Health, 2009
Budgeting

National budget
$956.2M costs for HIV
$210.3M of which is prevention
$0M of which is committed to PrEP

Current Funding
• PEPFAR, Gates Foundation, and Nike currently fund PrEP-related efforts ($39.5m allocated to DREAMS)¹
• PrEP research has been funded by BMGF, USAID, and NMHI/NIH
• Main fund sources for HIV/AIDS²:
  • >62% Bilateral funds (PEPFAR, UK)
  • >15% Public Funds (GoK)
  • >4% International non profits (CHAI)
• Current funding goes toward³:

<table>
<thead>
<tr>
<th></th>
<th>2015</th>
<th>2017</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline funding</td>
<td>$829M</td>
<td>$797M</td>
<td>$724M</td>
</tr>
<tr>
<td>Proposed funding</td>
<td>$829M</td>
<td>$852M</td>
<td>$940M</td>
</tr>
<tr>
<td>Resource needs</td>
<td>$956M</td>
<td>$948M</td>
<td>$833M</td>
</tr>
<tr>
<td>Gap</td>
<td>-13%</td>
<td>-10%</td>
<td>+13%</td>
</tr>
</tbody>
</table>

Remaining Gaps and Challenges
• It is likely that PrEP will not be funded by GoK, spelling the need for additional funding from external donors such as PEPFAR
• The overall HIV/AIDS funding gap (in $USD M) will continue until 2019³:

<table>
<thead>
<tr>
<th>Year</th>
<th>2015</th>
<th>2017</th>
<th>2019</th>
</tr>
</thead>
<tbody>
<tr>
<td>Baseline funding</td>
<td>$829M</td>
<td>$797M</td>
<td>$724M</td>
</tr>
<tr>
<td>Proposed funding</td>
<td>$829M</td>
<td>$852M</td>
<td>$940M</td>
</tr>
<tr>
<td>Resource needs</td>
<td>$956M</td>
<td>$948M</td>
<td>$833M</td>
</tr>
<tr>
<td>Gap</td>
<td>-13%</td>
<td>-10%</td>
<td>+13%</td>
</tr>
</tbody>
</table>

Summary
• Kenya’s HIV/AIDS total expenditures have risen over time, accounting for 2% of total country GDP. Over 68% of funding coming from external sources³
• The country has projected funding gaps to implement the new strategic plan (KASF)
• Kenya will strive to close funding gaps by maximizing program efficiency to reduce costs, and increasing domestic financing by 50% by 2019

Potential New Funding Sources
• Funders such as the Gates Foundation have shown initial commitments to further fund PrEP through current requests for proposals
• The National Hospital Insurance Fund (NHIF) will finance the Kenyan government’s universal health care. Kenya seeks to increase the number of contributors to this fund to cover costs of ART, and potentially fund additional HIV services
• Kenya HIV Trust/Investment Fund will raise national/county resources that will subsidize government HIV costs
• Determining the ability and willingness to pay for PrEP in a private healthcare setting might enable some cost-recovery

### Procurement & Distribution

#### Readiness for PrEP Introduction

<table>
<thead>
<tr>
<th>Readiness Factor</th>
<th>Progress</th>
</tr>
</thead>
</table>
| Regulatory **approval** of form(s) of oral PrEP by authorities | • Truvada approved for prevention by the Pharmacy and Poisons Board  
• Other forms of oral PrEP in pipeline |
| Effective **demand and supply forecasting** mechanisms for PrEP | • Strong supply chain management in place for ARVs, which will likely translate to PrEP readiness |
| Manufacturer identification and **contract** negotiation to purchase PrEP | • Not outside of demonstration projects |
| **Product and packaging** design to meet target population needs and preferences | • Currently a plastic pill bottle, to be refilled monthly; unknown if format will be consistent for other forms of oral PrEP |
| Development of **distribution plan** for PrEP to reach target populations | • NACC and other entities determining most effective channels and accompanying distribution plans  
• NASCOP’s RFPs for implementation of Prevention Revolution Roadmap will provide insight on distribution |
| Effective **distribution mechanisms** to avoid PrEP stock-outs in priority facilities | • Kenya has historically maintained a strong supply chain for ARVs, with limited instances of shortages. Likely to translate to PrEP |

#### Key Stakeholders
- **Gilead** licenses Truvada manufacturing globally. Its regional business partner in Kenya is currently Phillips Pharmaceuticals Limited
- **Pharmacy and Poisons Board** approves all new medications
- **Kenya Medical Supplies Authority**—central procurement agency under the MoH; partners with donors, county governments and community-based organizations (CBOs) to establish effective supply chains
- **CBOs and county level governments**—will be responsible for the local supply chain of PrEP

#### Key Strengths and Opportunities
- **Strong supply chain for ARVs**, with limited instances of shortages
- **Strong E- Medical Record System (EMR)** to ensure ART coordination and quality management system in place
- Although the details on who will procure PrEP are still unclear, the GoK has committed to supporting procurement for PrEP to make it available wherever needed (pharmacies, HIV clinics)

#### Key Emerging Considerations
- Need for additional data on **target populations** demand estimates and user preferences to inform demand forecasts
- Lack of clarity on who will **manufacture and distribute PrEP**—likely not a challenge when handled by current ARV channels but questions remain about additional delivery channels not administering ART
- **High price of Truvada**—could shift with emergence of alternatives oral PrEP drugs
PrEP Delivery Platforms

Key Stakeholders
- **PrEP TWG** – inform identification and planning for delivery channels
- **Comprehensive care clinics** (current ARV channels) - could distribute PrEP alongside HIV testing and treatment
- **Community-based organizations** - can support demand generation, distribution, and provide support for PrEP at the local level
- **County-level governments** – create county-level HIV plans as part of KASF delivery that would need to incorporate PrEP
- **Key population clinics** - provide HIV services to key populations directly

Key Strengths and Opportunities
- ARV clinics have a wide reach through ~2000 sites such as **comprehensive care centers and CBO-run clinics**. These could be leveraged for PrEP delivery
- Additional distribution plans are currently being developed by NACC, taking into account the voice of communities (via focus groups) to identify access needs, preferences, and support mechanisms necessary for effective distribution of PrEP to target populations
- Consider the ability and willingness to pay for PrEP through private health channels, some already reaching key populations (e.g., FHI’s Gold Star Network)

Key Emerging Considerations
- Health workers in many settings are not equipped to distribute PrEP to target populations, or address stigma
- **HIV testing kit shortages** could impede PrEP prescription/access
- Need better understanding of full landscape of potential PrEP distribution channels in order to most effectively reach target populations
- **Capacity-building** will be needed in order to equip non-ARV delivery channels as PrEP delivery/referral sites, including capacity to integrate with other care outlets (e.g., hospitals) to provide liver and kidney testing needed alongside PrEP
- **No ear-marked funding** for PrEP is available for capacity-building
### Current PrEP Delivery Channels

#### Demonstration Projects and Open Label Extensions

- **Background**
  - PrEP demonstration projects throughout Kenya have delivered PrEP through a number of projects. These projects include: Confidence Project; Fem-PrEP with adult women; LVCT and SWOP IPCP demo project with FSW, young women, and MSM; MP3-Youth with youth 15-24 years old; Partners PrEP demo project and OLE with sero-discordant couples.

- **Key Strengths**
  - Demo projects already reaching target populations at high risk of contracting HIV
  - Existing access to PrEP and associated testing, monitoring, and counselling services
  - Experienced staff highly knowledgeable about PrEP
  - Valuable insights from recruitment and retention efforts thus far
  - Low levels of stigma among staff working with PrEP users

- **Key Challenges**
  - Perception of PrEP as part of an “experiment” deters potential users fearing poor safety and efficacy of drug
  - Higher costs of delivery in demonstration project context

#### DREAMS

- **The DREAMS initiative** (Determined, Resilient, Empowered, AIDS-free, Mentored, and Safe women) will provide PrEP to young women in the districts of Homa Bay, Siaya, Kisumu and Nairobi beginning in 2016/2017. It is likely that oral PrEP in the form of Truvada will be donated by Gilead for use by DREAMS.

- **Targeted program** reaching high-risk (as identified by community-led criteria) adolescent girls to start 2016/17
- **PrEP delivery** coupled with behavior change activities and extensive counseling
- **Funding for PrEP** secured (Truvada donated by Gilead, program costs from DREAMS funding)
- **Potential to expand PrEP** throughout these districts given other investments to make PrEP available to DREAMS participants, including logistics, procurement, demand generation, and community buy-in efforts

- **DREAMS’ PrEP component** to reach only adolescent girls in communities where many other populations could benefit from PrEP
- **Reach limited to Homa Bay, Siaya, Kisumu and Nairobi**
### Potential PrEP Delivery Channels

<table>
<thead>
<tr>
<th>Comprehensive Care Centers &amp; other ART sites</th>
<th>Sexual and Reproductive Health (SRH) care providers</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Public (Gov't)</strong></td>
<td><strong>NGO</strong></td>
</tr>
<tr>
<td>• Public hospitals, clinics, and other health care centers</td>
<td>• NGO-run clinics, care centers, other HIV service programs including those specifically for key populations (e.g., SWOP, LVCT Health, FHI, PSI)</td>
</tr>
<tr>
<td><strong>Key Strengths</strong></td>
<td><strong>Key Challenges</strong></td>
</tr>
<tr>
<td>• Most visible to general population</td>
<td>• HCW stigma against target populations deters many from accessing care through these channels</td>
</tr>
<tr>
<td>• Systems guided and linked with county and national standards/agendas</td>
<td>• Can provide greater access to key populations (FSW, MSM, PWID)</td>
</tr>
<tr>
<td>• Can provide greater access to key populations (FSW, MSM, PWID)</td>
<td>• Effectively reach high-risk individuals with low/no stigma present in centers or among staff</td>
</tr>
<tr>
<td>• Frequent use of peer-educator programs, which might be critical to effective use and increased demand generation</td>
<td>• Opportunities to deliver through private channels accessing key populations such as FHI’s Gold Star Network clinics in Nairobi, the coastal region, and Riff Valley</td>
</tr>
<tr>
<td>• Over 2000 ART sites throughout Kenya</td>
<td>• Discrete access to PrEP without stigma for those who can afford it</td>
</tr>
<tr>
<td>• Well-integrated procurement and delivery systems</td>
<td>• Not dependent on aid</td>
</tr>
<tr>
<td>• Laboratory capacity for necessary PrEP monitoring in place</td>
<td></td>
</tr>
<tr>
<td>• HTC-trained staff</td>
<td></td>
</tr>
</tbody>
</table>

This is an area of focus for OPTIONS. Additional details expected by the end of 2016
Individual Uptake

Key Stakeholders
- **DREAMS** - will potentially have research and implementation practice for AGYW using PrEP that can be used to inform further scale-up (managed by Global Communities in Kenya)
- **Community-based and faith-based organizations** - will play a key role in reaching target populations locally and influencing community buy-in for PrEP
- **Local and national media** - to help accurate messaging on PrEP as an effective and safe prevention option

Key Strengths and Opportunities
- Some research exists on user preferences for PrEP in key populations (FSW, MSM, and sero-discordant couples), including: dosage patterns; willingness to consider using PrEP; potential demand for PrEP
- NASCOP has plans for additional research specifically on **delivery channels and access points for PrEP**
- Implementation stakeholders acknowledge the importance of **addressing stigma** in order to reach AGYW and sero-discordant couples

Key Emerging Considerations
- Stigma is a major concern for uptake. This includes both the stigma associated with HIV and those normally thought of as “high risk” populations, as well as stigma against young women who might be sexually active and seeking SRH care. There is a strong need to normalize PrEP and **create a supportive communication strategy** for its use
- **Awareness / demand** for PrEP is unknown; will require investment in demand generation (CHAI is currently doing initial demand generation research to be completed by Q4/16)
### Key End User Themes for PrEP

#### Key Considerations

| **Stigma** | **Early stigma lingers:** making PrEP widely available beyond key populations would help mitigate preconceptions of PrEP as an option only for FSW and MSM. This is important because most demo projects have been done with key populations. Any PrEP communications campaign will need to directly address the stigma associated with those populations.  
**Among health workers:** the challenges are twofold - healthcare workers have their own biases about who should be accessing birth control options and HIV prevention services, and they often lack the appropriate information and training to effectively provide a range of options to individuals to make informed decisions.  
**Youth and female-friendly spaces are critical and needed:** centers that are stigma-free, youth and female-friendly will facilitate uptake, but changes to facilities have been slow and insufficient. |
| **Drug Preconceptions** | **There are fears about developing resistance to ARVs while on PrEP, and developing physical side effects associated with ARVs.**  
**People recognize Truvada as an ARV and do not want to be seen taking it if they are HIV negative.** |
| **Messengers** | **Messages around PrEP need to be proactive, consistent, and come from multiple directions.** Important messengers include: national and county governments, ministries, CBOs, celebrities, religious leaders, healthcare workers, peers and various forms of media (e.g. print, radio, online). |
| **Messages** | **Risk perception:** young women in Kenya generally do not see themselves at high risk for HIV transmission. They are more focused on economic opportunity and education  
**PrEP as power:** PrEP could be framed as an option to protect oneself and the community. Also as something that is empowering and positive as opposed to shameful and incriminating. Ideas for messaging included statements such as: “Our own choice, our own power”  
**“Mpango Wa Kando”:** potential to build-off of previous national campaign about the consequences of extramarital affairs to appeal to potential PrEP users by highlighting the risk associated with their own/their partners’ conduct  
**PrEP for all:** ideas for inclusive messaging included statements such as “PrEP is for you, PrEP is for me” and “PrEP is for all of us.” |
Effective Use & Monitoring

Key Stakeholders

- **NACC** - holds country-wide responsibility to track KASF progress and HIV-related program success
- **CDC** - works closely with GOK and implementing partners to support lab systems and networks strengthening
- **National HIV Reference Laboratory (NHRL)** - leads policy and guidelines formulation on HIV-related lab services to strengthen country’s laboratory capacity

Key Emerging Considerations

- **Mechanisms for gathering local data** on PrEP impact are not established
- **Plans to increase effective use do not exist**; no roles have been assigned for generating the support systems needed to foster effective use at large
- **Interventions used to encourage effective use among demo project participants would likely be too costly in many real-life settings** (e.g., extensive counselling, use of peer educators)
- **Frequent, ongoing monitoring needs yet to be determined** and likely to both drive up costs of delivery and discourage ongoing use of PrEP

Readiness for PrEP Introduction

<table>
<thead>
<tr>
<th>Readiness Factor</th>
<th>Progress</th>
</tr>
</thead>
</table>
| **Established plans to support effective use and regular HIV, creatinine testing** that reflect the unique needs of target populations | • Effective use yet to be defined  
• While early considerations for encouraging and supporting effective use and adherence to regular testing are being discussed, specific strategies for target populations are not yet being created. |
| **Capacity** to provide ongoing HIV and creatinine level testing for PrEP users accessible to target populations | • While there is increasing HTC capacity for current efforts, gaps remain particularly for reaching target populations. Additionally, exact testing needs for PrEP are yet to be determined.  
• The national Monitoring and Evaluation Framework 2014/15-2018/19 is the foundation for monitoring progress toward HIV national goals (key indicators include reducing stigma related to HIV-AIDS, and reducing infections within key populations). |
| **Monitoring system** to support data collection for ongoing learning (e.g., rate of patients returning for 2nd visit, non-HIV STI rates) | |

Key Strengths and Opportunities

- **National monitoring and evaluation framework** includes priorities to increase funding toward healthcare capacity-building, reducing stigma, and targeting/prioritizing key populations such as MSM, FSW, youth
- Various surveys exist to collect national data on the HIV epidemic, including the situation room tool which will show live, local updates on HIV incidence and mortality
- **NASCOP** leading the development **PrEP M&E plans**
- Lessons on effective use from demo projects to learn from and build on include consistent regimens, structured follow-up, and counselling/community support
## Appendix B: Timelines for PrEP

<table>
<thead>
<tr>
<th>Quarter</th>
<th>Event Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Q1, 16</td>
<td>IPCP Kenya (LVCT Health and SWOP Kenya) study on PrEP for AGYW, MSM, and FSW</td>
</tr>
<tr>
<td>Q2, 16</td>
<td>Partners Demonstration Project on PrEP for sero-discordant couples</td>
</tr>
<tr>
<td>Q3, 16</td>
<td>MP3-Youth study to evaluate combination prevention for adolescent boys and girls</td>
</tr>
<tr>
<td>Q4, 16</td>
<td>POWER demonstration projects for adherence / delivery support for women</td>
</tr>
<tr>
<td>Q1, 17</td>
<td>EMOTION and GEMS studies</td>
</tr>
<tr>
<td>Q2, 17</td>
<td>Confidence Project study (LVCT Health and LSHTM) on PrEP acceptability reports</td>
</tr>
<tr>
<td>Q3, 17</td>
<td>Development of a national research agenda for HIV</td>
</tr>
<tr>
<td>Q4, 17</td>
<td>WHO PrEP Implementation Guidelines expected</td>
</tr>
<tr>
<td>2018</td>
<td>Kenya PrEP treatment guidelines and implementation plan expected</td>
</tr>
<tr>
<td>2019</td>
<td>DREAMS programming implemented in Homa Bay, Siaya, Kisumu, and Nairobi</td>
</tr>
<tr>
<td>2020</td>
<td>Next National AIDS Strategic Framework (KASF) developed</td>
</tr>
<tr>
<td></td>
<td>NASCOP RFPs for Prevention Revolution Roadmap implementation, including PrEP</td>
</tr>
<tr>
<td></td>
<td><strong>Exact timelines to be clarified</strong></td>
</tr>
</tbody>
</table>
Appendix C: References

- *National guidelines on HIV testing and counselling*, Ministry of Health, 2008
- *Kenya Fast Track Plan to end HIV/AIDS in Adolescents and Young People*, Ministry of Health, 2009
- *Cost of providing pre-exposure prophylaxis to prevent HIV infection among sex workers in Kenya*, Health Policy Project and Ministry of Health, 2014
- *Considerations for Rolling Out Oral PrEP to Target Populations through Social Marketing*, FHI 360 and IRDO, 2013
- *Barriers and facilitators to pre-exposure prophylaxis (PrEP) eligibility screening and ongoing HIV testing among target populations in Bondo and Rarieda, Kenya: Results of a consultation with community stakeholders*, BMC Health Services Research, 2014
- *Safety and Adherence to Intermittent Pre-Exposure Prophylaxis (PrEP) for HIV-1 in African Men Who Have Sex with Men and Female Sex Workers*, Plos One, 2012
- *Preferences for and Willingness to Use Antiretroviral Based HIV-1 Prevention Strategies among Kenyan HIV-1 Serodiscordant Couples*, NCBI, 2012
- *“Project to cut new HIV cases in girls, women launched”*, SciDevNet, 2015